Safety and Efficacy of NPS 1776 in the Acute Treatment of Migraine Headaches

PHASE2CompletedINTERVENTIONAL
Enrollment

189

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

June 30, 2004

Study Completion Date

July 31, 2004

Conditions
Migraine Headache
Interventions
DRUG

NPS 1776 (800 mg)

NPS 1776 (800 mg) powder

DRUG

PLACEBO

Placebo in non-carbonated fruit flavored drink (150 ml)

DRUG

NPS 1776 (400 mg)

NPS1776 in powdered form to be mixed with a non-carbonated fruit flavored drink

Trial Locations (22)

19107

Thomas Jefferson University Hospital/ Jefferson Headache Center, Philadelphia

27103

Piedmont Medical Research Associates, Winston-Salem

27401

Headache Wellness Center, Greensboro

33024

University Clinical Research, Inc, Pembroke Pines

35801

Medical Affiliated Research Center, Huntsville

37210

The Neurology Clinic, Portland

43623

Neurology Ctr. of Ohio, Toledo

48104

Michigan Head-Pain & Neurological Institute, Ann Arbor

60614

Diamond Headache Clinic, Chicago

63017

Mercy Health Research, Chesterfield

65804

Headache Care Center/ Clinvest, Springfield

72205

Clinical Study Centers, LLC, Little Rock

77004

Houston Headache Clinic, Houston

90404

California Medical Clinic for Headache, Santa Monica

92056

North County Neurological Associates, Oceanside

92705

Clinical Innovations, Santa Ana

94109

San Francisco Clinical Research Center, San Francisco

98405

Neurology & Neurosurgery Associates of Tacoma, Inc., PS, Tacoma

06902

The New England Center for Headache, Stamford

02481

MedTrial Boston, Wellesley Hills

08057

University of Medicine and Dentistry, New Jersey School of Osteopathic Medicine, Moorestown

07960

Neuroscience Center of Northern New Jersey, Morristown

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Shire

INDUSTRY

NCT00172094 - Safety and Efficacy of NPS 1776 in the Acute Treatment of Migraine Headaches | Biotech Hunter | Biotech Hunter